Endoscopic Therapy of Early Cancer in Barretts Esophagus

Participant visit requirements: Screening visit which will last 1 - 2 days, if assigned to photodynamic therapy, there will be a 3 day visit for treatment. Participants must return for a 1 day visit every three months for one year.

Inclusion criteria

• Non-recurrent adenocarcinoma in Barrett's Esophagus confirmed by two experienced gastrointestinal pathologists
• No evidence of submucosal invasion
• No evidence of metastatic disease in either regional or distal lymph nodes, or other organs
• Pre-entry CT scans of the upper abdomen and chest and Endoscopic Ultrasound (EUS) of the tumor and regional lymph nodes are required. Fusion PET scans are suggested for any indeterminate lesions
• Zubrod Performance Status 0-1
• Participants must be have oral intake of greater than 1700 calories a day
• Patient must not have had a second malignancy, other than curable non-melanoma skin cancer or cervical cancer in situ, unless disease free for greater than or equal to 3 years and deemed cured by their hematologist and/or oncologist
• Staging procedures should be performed prior to study entry
• All patients or legally authorized representative must sign a study-specific informed consent prior to randomization.

Exclusion criteria

• Prior major esophageal surgery
• Patients who are unable to tolerate endoscopic procedures
• Due to the possible toxic effects of photodynamic therapy and endoscopic sedation to embryos, pregnant or lactating women or men unable or unwilling to practice contraception are excluded
• Patients with an uncontrolled diabetes, heart disease, or hypertension
• Patient and/or legally authorized representative who are unable to comprehend the study requirements or who are not likely to comply with the study parameters.